Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes.

Abstract

Glycogen phosphorylase (GP) is a validated pharmaceutical target for the development of antihyperglycaemic agents. Phytogenic polyphenols, mainly flavonoids and pentacyclic triterpenes, have been found to be potent inhibitors of GP. These compounds have both pharmaceutical and nutraceutical potential for glycemic control in diabetes type 2. This review focuses mainly on the most successful (potent) of these compounds discovered to date. The protein-ligand interactions that form the structural basis of their potencies are discussed, highlighting the potential for exploitation of their scaffolds in the future design of new GP inhibitors.

• Authors: Demetres D Leonidas, Joseph M Hayes, Atsushi Kato, Vassiliki T Skamnaki, Demetra S M Chatzileontiadou, Anastassia L Kantsadi, Efthimios Kyriakis, Ben A Chetter, George A Stravodimos
• Journal: Current medicinal chemistry (Curr Med Chem) Vol. 24 Issue 4 Pg. 384-403 ( 2017) ISSN: 1875-533X [Electronic] United Arab Emirates
• PMID: 27855623 (Publication Type: Journal Article, Review)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Blood Glucose
• Enzyme Inhibitors
• Polyphenols
• Triterpenes
• Glycogen Phosphorylase

Topics

• Animals
• Blood Glucose (metabolism)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Enzyme Inhibitors (metabolism, pharmacology, therapeutic use)
• Glycogen Phosphorylase (antagonists & inhibitors, chemistry, metabolism)
• Humans
• Polyphenols (metabolism, pharmacology, therapeutic use)
• Triterpenes (metabolism, pharmacology, therapeutic use)